**Supplemental Digital Content 4.** Adverse events,from inclusion to Day 30.

|  |  |  |
| --- | --- | --- |
|  | Pleth variability index group(n=216) | Control group(n=222) |
| All adverse events, No. (%)  General disorders and administration site conditions, No. (%) Pain, No. (%)  Impaired healing, No. (%)  Blood and lymphatic system disorders, No. (% of adverse event) Anemia, No. (%) Vascular disorders, No. (%)  Hematoma, No. (%) Renal and urinary disorders, No. (%) Urinary retention, No. (%) | 123 (57)25 (19)15 (7)6 (3)25 (11)23 (11)15 (7)5 (2)8 (4)7 (3) | 126 (56)32 (14)12 (5)6 (3)18 (8)18 (8)11 (5)4 (2)16 (7)13 (6) |
| Adverse events grade >3, No. (%) Fracture, No. (%) Healing impaired, No. (%) Anemia, No. (%) Joint effusion, No. (%) Dislocation (+ joint dislocation + subluxation hip), No. (%) Sepsis, No. (%) Urinary retention, No. (%) Hematoma, No. (%) Atrial fibrillation, No. (%) Infection, No. (%) Device complication, No. (%) Dyspnea, No. (%) Embolic pneumonia, No. (%) Eschar, No. (%) Fall, No. (%) Hemorrhage, No. (%) Leukemic lymphoma, No. (%) Mobility decreased, No. (%) Pain, No. (%) Respiratory failure, No. (%) Urinary infection, No. (%)  | 27 (12)5 (2)2 (1)3 (1)2 (1)3 (1)1 (0)2 (1)2 (1)2 (1)0 (0)0 (0)0 (0)1 (0)1 (0)0 (0)0 (0)1 (0)1 (0)0 (0)1 (0)0 (0) | 14 (6)1 (0)3 (1)0 (0)1 (0)0 (0)1 (0)0 (0)0 (0)0 (0)2 (1)1 (0)1 (0)0 (0)0 (0)1 (0)1 (0)0 (0)0 (0)1 (0)0 (0)1 (0) |
| All serious adverse events, No. (%) Injury, poisoning and procedural complications, No. (%) Fracture, No. (%) Joint dislocation, No. (%) Fracture and joint dislocation, No. (%) Infection and infestations, No. (%) General disorders and administration conditions, No. (%) Vascular disorders, No. (%) | 20 (9)8 (4)5 (2)2 (1)7 (3)2 (1)2 (1)2 (1) | 14 (6)1 (0)0 (0)0 (0)0 (0)4 (2)4 (2)2 (1) |